Regional review
United Kingdom
Since leaving the EU, the United Kingdom operates its own regimes: the MHRA for medicines, UK REACH for chemical registration, and GB CLP for classification and labelling. EU registrations and EU-format labels are not automatically valid for Great Britain, and Northern Ireland follows separate arrangements under the Windsor Framework.
Sourcing considerations
The practical consequence is that a supplier compliant for the EU may not be compliant for Great Britain. Buyers should establish the UK REACH position for the substance, and for active substances confirm whether MHRA registration obligations fall on the importing entity.
Documentation requirements
Expect a specification, batch COA, and an SDS prepared to GB CLP rather than EU CLP. Buyers importing active substances for medicinal use will separately require documentation supporting MHRA import registration.
Import considerations
Great Britain and Northern Ireland can require different treatment for the same consignment, so the destination within the UK must be established before documentation is prepared. Customs declarations reference UK commodity codes and a GB EORI number.
Shipping and transport
Air freight follows IATA; road movements to and within the UK follow ADR as retained in UK law. Cold-chain routing should account for the additional customs step compared with intra-EU movements.
Questions buyers should ask
- What is the UK REACH status of this substance?
- Is the SDS prepared to GB CLP?
- Is the destination Great Britain or Northern Ireland?
- Does the importer hold MHRA registration where required?
- Which entity is the GB importer of record?